NASDAQ · PTGX
Healthcare · Biotechnology
$143.40
Down-$4.38 (-2.96%)
Updated Sep 16, 2026, 11:08 AM
SID Score
5.4/10
Composite research score
Smart Money
56/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PTGX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning PTGX.
PTGX research
Company profile and research snapshot.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | BMO Capital | Outperform | — |
| Sep 1, 2026 | Barclays | Overweight | — |
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 31, 2026 | Citigroup | Buy | — |
| Aug 17, 2026 | BMO Capital | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Protagonist Therapeutics, Inc. (PTGX) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 10:40 AM EDTCompany ParticipantsDinesh Patel - CEO,...
Yahoo · Sep 8, 2026
NEWARK, CA / ACCESS Newswire / September 8, 2026 / , Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock.
Benzinga · Sep 8, 2026
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common
Yahoo · Sep 6, 2026
On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The swing came as the company banked payments tied to two drugs moving from the lab bench to the […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PTGX.
